About
About Frequency Therapeutics Inc
As of November 3, 2023, Frequency Therapeutics, Inc. was acquired by Korro Bio, Inc., in a reverse merger transaction. Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
Visit company website
5 years, 4 months ago
Frequency Therapeutics, Inc is currently in a long term downtrend where the price is trading 63.6% below its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.4.
Frequency Therapeutics, Inc's total revenue rose by 111.3% to $10M since the same quarter in the previous year.
Its net income has increased by 99.8% to $-10K since the same quarter in the previous year.
Finally, its free cash flow grew by 36.2% to $-19M since the same quarter in the previous year.
Based on the above factors, Frequency Therapeutics, Inc gets an overall score of 4/5.